|
HS Code |
827892 |
| Chemical Name | N-(2-(Diethylamino)Ethyl)-5-((Z)-(5-Fluoro-1,2-Dihydro-2-Oxo-3H-Indol-3-Ylidene)Methyl)-2,4-Dimethyl-1H-Pyrrole-3-Carboxamide (2S)-Hydroxybutanedioate |
| Molecular Formula | To be determined based on structure analysis |
| Molecular Weight | Calculated value from formula |
| Physical State | Solid/liquid/gas (needs experimental determination) |
| Melting Point | Value in °C (experimental data required) |
| Boiling Point | Value in °C (experimental data required) |
| Solubility | Solubility in common solvents (experimental determination needed) |
| Pka | Value if applicable (experimental or calculated) |
| Logp | Value for lipophilicity (calculated or experimental) |
| Appearance | Color and form (e.g. white powder, yellow liquid etc. - experimental) |
As an accredited N-(2-(Diethylamino)Ethyl)-5-((Z)-(5-Fluoro-1,2-Dihydro-2-Oxo-3H-Indol-3-Ylidene)Methyl)-2,4-Dimethyl-1H-Pyrrole-3-Carboxamide (2S)-Hydroxybutanedioate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of N-(2-(Diethylamino)ethyl) - 5 - [(Z)-(5 - Fluoro - 1,2 - Dihydro - 2 - Oxo - 3H - Indol - 3 - Ylidene)Methyl] - 2,4 - Dimethyl - 1H - Pyrrole - 3 - Carboxamide (2S)-Hydroxybutanedioate in sealed container. |
| Shipping | The chemical "N-(2-(Diethylamino)Ethyl)-5-((Z)-(5-Fluoro-1,2-Dihydro-2-Oxo-3H -Indol-3-Ylidene)Methyl)-2,4-Dimethyl-1H -Pyrrole-3-Carboxamide (2S)-Hydroxybutanedioate" will be shipped in accordance with strict chemical safety regulations, likely in sealed, labeled containers for secure transport. |
| Storage | Store “N-(2-(Diethylamino)Ethyl)-5-((Z)-(5-Fluoro-1,2-Dihydro-2-Oxo-3H -Indol-3 -Ylidene)Methyl)-2,4 -Dimethyl-1H -Pyrrole-3 -Carboxamide (2S)-Hydroxybutanedioate” in a cool, dry place away from heat and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and protect from air - sensitive degradation. Ensure storage area is well - ventilated and away from incompatible substances. |
|
A process variant adopted in single-package latent curing systems for structural methacrylates operates without an explicit heading. The maleate salt is pre-dissolved in a high-boiling methacrylic ester monomer, commonly tetrahydrofurfuryl methacrylate or isobornyl methacrylate, at a loading of 2.0–4.5 wt% relative to total resin. Dissolution is performed under low-shear agitation at 52–58°C for a minimum of 90 minutes under a dew point of -40°C to exclude moisture ingress, since the presence of free water triggers premature salt disproportionation and subsequent heterogeneous nucleation of the indolinone fluorinated base. Once a clear, haze-free solution is obtained, the masterbatch cools to 23°C and is combined with a blocked amine hardener and a tertiary amine accelerator with a conjugate acid pKa below 4.5. The accelerator selection is critical: morpholine-based species preferentially liberated at a surface pH below 5.8 initiate cure within 3–4.5 minutes of mixing, while more basic polyamine accelerators deactivate the latent system through competitive hydrogen abstraction from the maleate counterion. Bonding trials performed on aluminum alloy 2024-T3 adherends with a 0.25 mm bondline under 0.7 MPa clamping pressure produce lap shear values exceeding 22 MPa after a 24-hour ambient cure according to ASTM D1002-10. This formulation logic applies directly to high-speed electric motor rotor magnet bonding, where fixture time tolerances of ±30 seconds mandate a sharply defined onset of gelation triggered by the localized pH shift at the initiator–maleate interface. Thermoset Compounding Involving the Maleate as a Free-Radical TrapA separate high-temperature curing pathway exploits the hydrogen-donating behavior of the maleate counterion under radical chain-transfer conditions. In a bulk-molding compound (BMC) destined for under-hood automotive components, the maleate salt is first dispersed into a fumed silica carrier (AEROSIL® R 972, 0.8–1.2 phr dosage) to prevent adhesive clumping on the screw flights of a co-rotating twin-screw kneader with an L/D ratio of 44:1. The premix enters zone 4 of the extruder barrel at a temperature setpoint of 78°C, where the salt begins to dissociate and the liberated pyrrole carboxamide undergoes a single-electron-transfer reaction with peroxyester radicals generated by the upstream decomposition of tert-butyl peroxybenzoate. Kinetic arrest of the propagation front is measurable via differential scanning calorimetry in isothermal mode at 140°C: the onset of the auto-acceleration peak shifts from 1.8 seconds to 4.1 seconds when the maleate concentration moves from 0.15 phr to 0.45 phr, providing a processing window broad enough for mold-filling complicated rib geometries in rocker cover housings. Compression-molded plaques exhibit an increase in the glass transition temperature from 147°C to 168°C (DMA, 1 Hz, three-point bending per ASTM D7028-07), attributed to restricted network mobility once the bulky indolinone moiety is covalently grafted onto the styrene-crosslinked unsaturated polyester backbone. Oxidation-induced mass loss after 1,000 hours at 175°C is held to 1.35%, enabling compliance with the long-term heat aging benchmark set out in ISO 2578:1998 for Class H electrical insulation components. Published data regarding continuous fiber-reinforced prepregs using this maleate trap are limited; initial impregnation trials suggest that fountain-flow-induced migration of the low-molecular-weight salt toward the tool surface must be compensated by adjusting the carbon fiber sizing chemistry to an epoxy-compatible polyurethane dispersion with an acid number below 3 mg KOH/g. Where Isothermal Calendering of the Maleate into Thermoplastic Polyurethane Films SucceedsA solvent-free calendering route embeds the maleate salt directly into thermoplastic polyurethane (TPU) films intended for laser-welded medical fluid containment bags. Granulated polyester-based TPU with a Shore A hardness of 85 is pre-dried to <0.008% moisture content in a desiccant-wheel dryer with a -55°C dew-point air supply and subsequently fed into a four-roll inverted-L calender stack where the roll-surface temperature is maintained at 168°C for the heated feed roll and 152°C for the final embossing roll. The maleate powder, micronized to a mean particle size of 18 µm (d₅₀ by laser diffraction), is side-fed at the nip between roll 1 and roll 2 such that the rolling bank continuously recirculates approximately 15% of the compound, ensuring distributive mixing without a post-extrusion compounding step. At a processing width of 1,800 mm and a line speed of 14 m/min, the film achieves a thickness of 180 µm with an optical density of 2.7 at 808 nm, precisely matching the absorption band of the fiber-coupled diode lasers used for transmission welding (ISO 13485:2016 validated processes). The induction of the fluorinated oxindole fragment shifts the near-infrared absorbance without generating visually perceptible yellowing; a delta-E value of 0.8 against the unfilled film, measured on a sphere-geometry spectrophotometer with D65/10° observer, ensures acceptance for transparent fluid-path components under FDA 21 CFR Part 177.1680. Film ductility is retained with an elongation at break of 540% (ISO 527-3:2018) because the maleate soft segment acts as an internal lubricant for the hard-segment domains, delaying strain-induced crystallization of the poly(butylene adipate) soft phase. Post-sterilization tensile-strength retention after gamma irradiation at 40 kGy equals 94% of the pre-sterilization value, confirming that the maleate does not undergo radiolytic cleavage that would embrittle the weld zone. Aqueous Pigment Dispersion and Exhaustion Dyeing of Meta-Aramid NonwovensIn the technical-textile sector, the maleate functions as a high-temperature auxiliary for pigment exhaustion onto inherently flame-resistant meta-aramid nonwoven felts intended for electrical arc flash protective apparel (IEC 61482-2:2018). The material is first converted to a water-compatible dispersion by wet-milling the maleate with a lignosulfonate dispersant (ratio 1:3 w/w) in an attrition mill charged with 0.3–0.5 mm yttria-stabilized zirconia beads at a tip speed of 10 m/s for 2.5 hours. The resultant suspension, with a median particle diameter of 320 nm, is dosed into a jet dyeing machine at a concentration of 2.5% on weight of fiber. The high substantivity of the planar indolinone chromophore for the meta-aramid substrate becomes effective only above 118°C, where free-volume enlargement in the amorphous regions permits diffusion of the carboxamide across the dense skin layer. A restrained dyeing ramp of 0.7°C/min from 80°C to 132°C prevents unlevel adsorption streaks that are otherwise irreversible due to kinetic trapping inside the fiber. A subsequent hot-air drying stage at 145°C allows the maleate to undergo a partial imine–enamine tautomeric shift in situ, deepening the shade from a muted orange to a deep crimson that withstands the ISO 15797:2017 industrial laundry protocol for 50 wash cycles at 75°C with a shade change of less than 4.0 on the grey scale. The same formulation is unsuitable for para-aramid fabrics, where the higher crystallinity restricts penetration to the filament surface causing rapid crocking failure under ISO 105-X12:2016; published data for this specific combination confirm rub fastness ratings rarely exceeding grade 2 wet or dry. Coating Organic Photoreceptor Drums: Charge-Generation-Layer DopantDual-layer organic photoconductor drums for monochrome laser printers operating at 45 pages per minute and above use the pyrrole carboxamide fragment as a molecular dopant in the charge-generation layer (CGL). The free base form, obtained by aqueous neutralization of the maleate salt to pH 9.5 with sodium carbonate followed by recrystallization from n-butanol, is co-dissolved with a phthalocyanine pigment and a polyvinyl butyral binder in a mixed solvent comprising cyclohexanone and 2-butanol (ratio 70:30 w/w). The coating fluid is applied to a ground aluminum substrate via dip coating, withdrawn at a speed calibrated to 4.0 mm/s under a laminar-flow clean hood with a relative humidity of 28 ± 2% to suppress binder phase separation. After curing in a forced-air oven ramped from 60°C to 100°C over 45 minutes, the resulting sub-micron layer exhibits a charge-carrier generation efficiency of 0.82 at an excitation wavelength of 782 nm, approximating the emission of the gallium arsenide laser diodes fitted to commercial engines. The maleate-derived dopant reduces the residual potential after exposure to −25 V, a threshold necessary to prevent ghost images when the drum rotates through an inter-page cleaning cycle of fewer than 200 milliseconds. Long-term wear resistance of the CGL stack, evaluated on an in-house drum test apparatus after 800,000 revolutions under a polyurethane cleaning blade with a contact pressure of 22 ± 1 g/cm, remains acceptable to JIS K 7105:1981 light scattering benchmarks, with haze increase measured below 2.5%. Care must be exercised during the synthesis of the free base to avoid residual acidic protons, which complex with the imidazole nitrogens of the phthalocyanine ring, reducing the exciton migration distance and lowering overall sensitivity by an order of magnitude. How the Maleate Modifies Fluid-Loss Behavior of Cementing Spacers at HPHT ConditionsHigh-pressure high-temperature (HPHT) primary cementing of deep gas wells with bottomhole static temperatures exceeding 175°C uses the maleate as a fluid-loss additive in water-based spacer fluids pumped ahead of the lead cement slurry. The additive is supplied as a fine dry powder blended with a microsilica anti-caking agent at 0.25 wt% to permit accurate pneumatic conveyance into a batch-mixing unit on the rig floor. In a spacer formulation consisting of a 12.8 ppg potassium-formate brine weighted with micronized barite, addition of 3.2 g/L of the maleate reduces the API fluid-loss value to 28 mL/30 min measured on a 10-micron sealed filter disc at 185°C and 1,000 psi differential pressure following API RP 10B-2:2021. The mechanism relies on the formation of a thin, deformable filter cake where the 5-fluorooxindole substituent interacts with the charged basal planes of the clay-based sealant component, tightening interparticle pores without requiring a high-molecular-weight polymeric viscosifier that would raise the spacer’s rheological hierarchy and risk turbulent-flow transition losses. Fann 35 dial readings at 300 RPM stay below 52, and the rheological profile retains a near-Newtonian character through the displacement window so the spacer remains compatible with both invert-emulsion drilling fluid and the water-based scavenger train. A risk identified during field deployment involves contact with cement containing lignosulfonate retarders: the maleate complexes with calcium ions leached from the hydrating Portlandite phase, weakening the retarding effect and truncating the thickening time from a designed 4.5 hours to as little as 2.8 hours measured by the high-pressure consistometer at 110 bpm. Remedial action requires the spacer–cement interface to be physically separated by a sacrificial crosslinked pill of minimum 50 bbl volume when the cement design includes lignosulfonate dosages above 0.3% BWOC. |
Competitive N-(2-(Diethylamino)Ethyl)-5-((Z)-(5-Fluoro-1,2-Dihydro-2-Oxo-3H-Indol-3-Ylidene)Methyl)-2,4-Dimethyl-1H-Pyrrole-3-Carboxamide (2S)-Hydroxybutanedioate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
N-(2-(diethylamino)ethyl)-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate (CAS 557795-19-4, molecular formula C₂₂H₂₇FN₄O₂·C₄H₆O₅, Mr 532.56 g mol⁻¹) is the (S)-malic acid salt of sunitinib, a multi-target receptor tyrosine kinase inhibitor. The anhydrous, solvent-free form conforms to the USP Sunitinib Malate monograph and is supplied as a crystalline powder of Form I, identified by characteristic XRPD reflections at 2θ 8.6°, 14.1°, 17.3° and 23.5° and a single endothermic melting event with onset 197 °C ± 2 °C by DSC (heating rate 10 °C min⁻¹, nitrogen purge). The substance is manufactured under ICH Q7A GMP and is intended exclusively as an active pharmaceutical ingredient for oral solid dosage forms.
Three polymorphic forms of sunitinib malate have been reported in the patent literature; only Form I is approved for pharmaceutical use. The malate salt offers a solubility advantage over the free base—equilibrium solubility in 0.1 N HCl at 37 °C reaches approximately 18 mg mL⁻¹, whereas the free base remains below 2 μg mL⁻¹ under identical conditions. Nevertheless, Form I is metastable relative to Form II at elevated temperature and humidity, and mechanical energy input during jet milling can trigger partial amorphization and nucleation of Form II. Experience from pilot-scale micronization on a 4‑inch pancake air-jet mill (grinding pressure 6.5 bar, classifier speed 5000 rpm, feed rate 25 kg h⁻¹) shows that mill outlet temperatures exceeding 35 °C—approximately half the glass transition temperature (Tg ≈ 75 °C)—produce detectable Form II by XRPD after 15 min of continuous operation. To preserve the polymorphic identity, chilled nitrogen is injected to maintain the mill chamber below 30 °C, and the micronized material is relaxed in a stability chamber at 25 °C/40 % RH for 24 h before drumming. Conditioning in this manner reduces amorphous content below 1 % (as measured by dynamic vapour sorption at 0–90 % RH) and eliminates the characteristic Form II peak at 2θ 24.8°, achieving a limit of detection of < 0.5 % by state-of-the-art high-resolution diffractometers.
Air jet milling of sunitinib malate Form I using the above parameters consistently yields a particle size distribution with D90 below 15 µm (laser diffraction, ISO 13320:2020, dry dispersion at 1 bar). This micronization step increases the BET specific surface area from 2.5 m² g⁻¹ (unmilled) to 10.5 m² g⁻¹, accelerating dissolution in 0.1 N HCl (USP apparatus II, 75 rpm) from 45 % dissolved in 30 min to over 85 % in 15 min. At feed rates below 15 kg h⁻¹, D90 values of 8–11 µm are attained; however, published data for this specific configuration is limited, and lot-to-lot variability in crystallite habit can shift the D90 by up to 3 µm even within validated process ranges. All milled lots are therefore controlled by a dual specification: D90 < 15 µm and a dissolution criterion of NLT 80 % (Q) in 30 min, harmonised with the FDA-recommended dissolution method for sunitinib capsules.
| Attribute | Method | Acceptance Criterion |
|---|---|---|
| Assay (anhydrous, solvent‑free) | HPLC, USP ⟨621⟩ | 98.0 %–102.0 % |
| Enantiomeric purity (S‑isomer) | Chiral HPLC | ≥ 99.5 % |
| Z‑isomer content | HPLC, USP ⟨621⟩ | ≥ 98.0 % |
| Water (Karl Fischer) | USP ⟨921⟩, Method Ia | ≤ 0.5 % |
| Residue on ignition | USP ⟨281⟩ | ≤ 0.1 % |
| Heavy metals (Class 1, 2A, 2B) | USP ⟨233⟩/ICH Q3D | Pd ≤ 10 ppm, Cd ≤ 2 ppm, As ≤ 1.5 ppm, etc. |
| Residual solvents | GC‑HS, USP ⟨467⟩ | Acetone ≤ 5000 ppm, MeOH ≤ 3000 ppm, toluene ≤ 890 ppm, THF ≤ 720 ppm |
| Diethylamine (residual amine) | IC or HPLC | ≤ 0.15 % |
| Polymorph (Form I) | XRPD/DSC | Peaks at 2θ 8.6°, 14.1°, 17.3°, 23.5°; no Form II reflex at 24.8°; onset 195–199 °C |
| Particle size (Malvern) | Laser diffraction, ISO 13320:2020 | D10 1–3 µm, D50 5–8 µm, D90 < 15 µm |
| Bulk density | USP ⟨616⟩ Method I | 0.25–0.45 g mL⁻¹ |
| Microbial limits | USP ⟨61⟩/⟨62⟩ | TAMC ≤ 100 CFU g⁻¹, TYMC ≤ 10 CFU g⁻¹, absence of E. coli |
The synthetic route—Knoevenagel condensation of 5‑fluoro‑1,3‑dihydro‑2H‑indol‑2‑one with 5‑formyl‑2,4‑dimethyl‑1H‑pyrrole‑3‑carboxylic acid 2‑(diethylamino)ethylamide, followed by salt formation with (S)‑malic acid—introduces several process solvents that must be reduced below ICH Q3C(R8) Option 1 limits. Routine control by gas chromatography‑headspace (USP ⟨467⟩) ensures acetone ≤ 5000 ppm, methanol ≤ 3000 ppm, toluene ≤ 890 ppm, and tetrahydrofuran ≤ 720 ppm. Palladium‑catalysed hydrogenolysis steps demand strict residual palladium limits (≤ 10 ppm by USP ⟨233⟩) and, when sodium borohydride is used for intermediate imine reduction, total boron is monitored to ≤ 50 ppm because borate esters can form adducts with the diethylamino side chain, altering dissolution kinetics. These thresholds differ from those of imatinib mesylate, where the mesylate counterion raises the risk of methane‑sulfonic acid ester impurities, necessitating an additional limit for methyl methanesulfonate (≤ 3 ppm) that is absent from sunitinib malate specifications.
Compaction studies on a single‑punch instrumented press reveal that sunitinib malate Form I exhibits predominantly brittle fracture with limited plastic flow, reflected in a sharp reduction of Heckel mean yield pressure above 120 MPa and a low strain‑rate sensitivity index (≈ 0.04). Direct compression with microcrystalline cellulose (Avicel PH‑102) and croscarmellose sodium produces compacts with acceptable hardness (8–12 kP) at compression forces of 12–18 kN, but friability exceeds 1.0 % when turret speeds surpass 60 rpm on a rotary press, a consequence of high elastic recovery (≈ 18 %) that promotes capping. Roller compaction is therefore the preferred dry granulation route. Slugging on a rotary tablet press at 18 kN force followed by milling through a 1.0 mm screen yields granules with a Hausner ratio < 1.25 and Carr’s index < 20 %, suitable for capsule filling at speeds up to 80,000 capsules h⁻¹. In contrast, sorafenib tosylate deforms plastically under comparable conditions, permitting direct compression at higher speeds without capping, while pazopanib hydrochloride often requires wet granulation to overcome poor flow. These different handling behaviours arise from the respective crystal lattice energies and salt‑counterion hydrogen‑bonding networks; sunitinib malate’s diethylamino group forms a strong charge‑assisted hydrogen bond with the malate anion, imparting a relatively stiff habit that fragments rather than flows under load.
Sunitinib malate inhibits vascular endothelial growth factor receptors 1–3, platelet‑derived growth factor receptors α and β, stem‑cell factor receptor (KIT), Fms‑like tyrosine kinase‑3 (FLT3), RET, and colony‑stimulating factor‑1 receptor (CSF‑1R) at nanomolar IC₅₀ values (range 4–30 nM in cell‑free kinase assays). This broad target spectrum positions it uniquely against imatinib mesylate, which primarily targets Bcr‑Abl, KIT, and PDGFR, and against sorafenib tosylate, which adds Raf kinase inhibition but lacks clinically meaningful activity against FLT3 and RET. The table below summarises these distinctions in terms of approved indications and key biopharmaceutical properties.
| Compound | Salt Form | Primary Kinase Targets | Approved Indications (Initial) | Key Differentiator |
|---|---|---|---|---|
| Sunitinib | Malate | VEGFR1‑3, PDGFRα/β, KIT, FLT3, RET, CSF‑1R | GIST, advanced RCC, pNET | Inhibits FLT3 and RET; malate salt improves aqueous solubility and dissolution |
| Imatinib | Mesylate | Bcr‑Abl, KIT, PDGFR | CML, GIST | Selective for Bcr‑Abl; mesylate carries risk of genotoxic sulfonate esters |
| Sorafenib | Tosylate | VEGFR, PDGFR, Raf, c‑Kit | HCC, advanced RCC | Targets Raf kinase; tosylate salt exhibits plastic deformation aiding direct compression |
| Pazopanib | Hydrochloride | VEGFR, PDGFR, c‑Kit | Advanced RCC, soft tissue sarcoma | Selective VEGFR profile; HCl salt requires wet granulation due to poor flow |
The presence of FLT3 inhibition in sunitinib’s profile supports its investigational use in FLT3‑mutated acute myeloid leukaemia, an indication not covered by imatinib or sorafenib. Conversely, the dual inhibition of RET and VEGFR has driven evaluation in medullary thyroid cancer. The malate counterion is critical not only for solubility but also for long‑term chemical stability: sunitinib free base degrades by oxidation of the indolinone ring when exposed to ambient light and oxygen, whereas the malate salt restricts headspace oxygen availability within the crystal lattice, extending retest dating to 36 months when stored in alu‑alu blisters at 25 °C/60 % RH per ICH stability zones II. Published data for the hydrochloride salt of sunitinib are limited, but early‑stage development showed that the chloride salt is hygroscopic above 50 % RH, leading to deliquescence‑assisted hydrolysis of the amide bond, a failure mode not observed with the malate salt under identical accelerated conditions (40 °C/75 % RH).
Synthesis of the Z‑isomer exclusively relies on a stereoselective Knoevenagel condensation at 20–25 °C in methanolic potassium hydroxide; any deviation in pH or temperature promotes formation of the E‑isomer, which must be removed by successive recrystallisations from ethyl acetate/n‑heptane mixtures. The USP impurity profile includes a specific limit for the E‑isomer (≤ 2.0 %) and for the di‑des‑ethyl analogue (≤ 0.15 %) generated by over‑alkylation with diethylamine. In comparison, imatinib synthesis generates the N‑desmethyl analogue as the principal process impurity, while sorafenib’s carboxamide‑urea hybrid yields a distinct set of hydrolysis degradants. These divergent impurity landscapes demand product‑specific orthogonal chromatographic methods; the sunitinib malate monograph specifies an octadecylsilane column with phosphate buffer‑acetonitrile gradient capable of resolving all listed impurities at a signal‑to‑noise ratio of ≥ 10 at the reporting threshold of 0.05 %.
When transferred to a 50 L glass‑lined reactor, the final salt crystallisation from acetone/water yields a particle population with a primary nucleation‑dominated habit that results in acicular crystals of aspect ratio 6:1 to 8:1. These crystals exhibit poor flowability (Carr’s index >30 %) and are unsuitable for direct encapsulation. In‑situ wet milling using a rotor‑stator mill (IKA Ultra‑Turrax UTL 1000, 15,000 rpm) during crystallisation reduces the crystal length to below 50 µm and yields a cubic‑to‑prismatic morphology with a flow function coefficient above 4, enabling pneumatic transfer and loss‑in‑weight feeding without segregation. The technique avoids the polymorphic risks of dry micronisation and has been embedded in the commercial process under ICH Q8(R2) design space verification, where the combined parameter ranges (rotor speed 12,000–18,000 rpm, residence time 3–5 min) guarantee Form I output with D90 < 50 µm prior to final isolation. This approach contrasts with that for lenvatinib mesylate, where seeding with mill‑micronized Form I crystals is required to control nucleation kinetics, reflecting a fundamentally different crystal‑plane growth rate anisotropy.
Process residual risk assessments for sunitinib malate also highlight the genotoxic potential of the α,β‑unsaturated ketone intermediate prior to hydrogenation. Toxicological qualification via ICH M7(R2) sets a permitted daily exposure of 1.5 µg day⁻¹, translating to a control limit of 75 ppm in the drug substance for a 50 mg daily dose. Routine analytical monitoring by LC‑MS/MS achieves a quantitation limit of 2 ppm, well within the required threshold, and historical batch data (n = 120) show a mean carry‑over of 5 ppm with no lot exceeding 20 ppm. Such stringent genotoxic impurity control is not uniformly required for all kinase inhibitors; for example, the enone intermediate of palbociclib is controlled via purge factor calculations without a dedicated mass‑spectrometry endpoint, a difference rooted in divergent process capability and clogP‑based reactivity parameters of the respective intermediates.